- $1.72bn
- $491.63m
- $78.50m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.87 | ||
Price to Tang. Book | 2.87 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 18.86 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -41.27% | ||
Return on Equity | -64.17% | ||
Operating Margin | -421.93% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 42.98 | 21.8 | 46.7 | 131.4 | 78.5 | 215.1 | 197.3 | 40.53% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Directors
- Timothy Shannon NEC (62)
- John Houston PRE (61)
- Sean Cassidy CFO (51)
- Ian Taylor CSO (58)
- Ronald Peck OTH (55)
- Linda Bain DRC (50)
- Wendy Dixon IND (65)
- Edward Kennedy IND (59)
- Bradley Margus IND (60)
- Briggs Morrison IND (62)
- Leslie Norwalk IND (55)
- Liam Ratcliffe IND (57)
- Laurie Smaldone Alsup IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 9th, 2014
- Public Since
- September 27th, 2018
- No. of Shareholders
- 35
- No. of Employees
- 445
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 68,648,061
- Address
- 5 Science Park, NEW HAVEN, 06511-1966
- Web
- https://www.arvinas.com/
- Phone
- +1 2035351456
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ARVN
Q3 2024 Arvinas Inc Earnings Release
Q4 2024 Arvinas Inc Earnings Release
Similar to ARVN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:48 UTC, shares in Arvinas are trading at $25.05. This share price information is delayed by 15 minutes.
Shares in Arvinas last closed at $25.05 and the price had moved by -0.83% over the past 365 days. In terms of relative price strength the Arvinas share price has underperformed the S&P500 Index by -21.56% over the past year.
The overall consensus recommendation for Arvinas is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArvinas does not currently pay a dividend.
Arvinas does not currently pay a dividend.
Arvinas does not currently pay a dividend.
To buy shares in Arvinas you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $25.05, shares in Arvinas had a market capitalisation of $1.72bn.
Here are the trading details for Arvinas:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARVN
Based on an overall assessment of its quality, value and momentum Arvinas is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arvinas is $65.78. That is 162.59% above the last closing price of $25.05.
Analysts covering Arvinas currently have a consensus Earnings Per Share (EPS) forecast of -$3.51 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arvinas. Over the past six months, its share price has underperformed the S&P500 Index by -48.88%.
As of the last closing price of $25.05, shares in Arvinas were trading -26.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arvinas PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $25.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arvinas' management team is headed by:
- Timothy Shannon - NEC
- John Houston - PRE
- Sean Cassidy - CFO
- Ian Taylor - CSO
- Ronald Peck - OTH
- Linda Bain - DRC
- Wendy Dixon - IND
- Edward Kennedy - IND
- Bradley Margus - IND
- Briggs Morrison - IND
- Leslie Norwalk - IND
- Liam Ratcliffe - IND
- Laurie Smaldone Alsup - IND